Effects of a four-strain probiotic on inflammatory markers in Parkinson’s disease: a multicentre randomised controlled trial (the SymPD study) (N5.001)

Valentina Leta; Gargi Mandal; Pavlos Zinzalias; Juliet Staunton; Lucia Batzu; Dhaval Trivedi; Kristina Rosqvist; Jonathan Timpka; Trinette van Vliet; Aleksandra Podlewska; Miriam Parry; Daniel J. van Wamelen; Alexandra Rizos; Guy Chung‐Faye; Per Odin; Carmine M. Pariante; Alessandra Borsini; К. Ray Chaudhuri

doi:10.1212/wnl.0000000000205490

Abstract

To evaluate the effects of a four-strain probiotic (Lacticaseibacillus rhamnosus, Enterococcus faecium, Lactobacillus acidophilus, Lactiplantibacillus plantarum) on plasma levels of inflammatory markers in patients with Parkinson's disease (PD) and symptomatic constipation recruited to the SymPD trial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leta et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db6435876773c9 https://doi.org/10.1212/wnl.0000000000205490

View Full Paper

Ask AI

Bookmark

Share

Effects of a four-strain probiotic on inflammatory markers in Parkinson’s disease: a multicentre randomised controlled trial (the SymPD study) (N5.001)

Abstract

Discussion

Cite This Study

Effects of a four-strain probiotic on inflammatory markers in Parkinson’s disease: a multicentre randomised controlled trial (the SymPD study) (N5.001)

Abstract

Discussion

Cite This Study

Keep reading

Keep reading